Biodesix Inc (NASDAQ: BDSX) kicked off on Friday, down -5.40% from the previous trading day, before settling in for the closing price of $8.33. Over the past 52 weeks, BDSX has traded in a range of $3.44-$23.56.
During the last 5-year period, the sales growth of Healthcare Sector giant was 69.26%. While this was happening, its average annual earnings per share was recorded 22.00%. With a float of $3.31 million, this company’s outstanding shares have now reached $7.95 million.
Biodesix Inc (BDSX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Diagnostics & Research Industry. The insider ownership of Biodesix Inc is 52.12%, while institutional ownership is 21.34%. The most recent insider transaction that took place on Nov 10 ’25, was worth 99. In this transaction Chief Accounting Officer of this company sold 13 shares at a rate of $7.62, taking the stock ownership to the 936 shares. Before that another transaction happened on Nov 10 ’25, when Company’s Chief Development Officer sold 23 for $7.62, making the entire transaction worth $175. This insider now owns 7,939 shares in total.
Biodesix Inc (BDSX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -1.2 earnings per share (EPS), higher than consensus estimate (set at -1.33) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.00% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 41.37% during the next five years compared to 69.26% growth over the previous five years of trading.
Biodesix Inc (NASDAQ: BDSX) Trading Performance Indicators
Take a look at Biodesix Inc’s (BDSX) current performance indicators. Last quarter, stock had a quick ratio of 1.76. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.37, a number that is poised to hit -0.90 in the next quarter and is forecasted to reach -2.43 in one year’s time.
